Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 49 participants, all of whom were in a single group receiving ondansetron therapy. All 49 participants completed the study with none dropping out. The trial was measuring rates of nausea and vomiting in participants receiving ondansetron, and comparing those rates to historical figures from the Fred Hutchinson Cancer Research Center (FHCRC). Nausea was measured using a standard tool called the MAT (Multinational Association of Supportive Care in Cancer Antiemesis Tool), which gives a score from 0 to 10 where a higher score means worse nausea. Vomiting was recorded simply as present or absent. The reported data shows the following participant counts across the nausea and vomiting measurements: 23, 9, 12, and 9 participants respectively across the reported data points. However, the labels or time points that these four numbers correspond to were not clearly described in the structured data as submitted to ClinicalTrials.gov, so it is not possible to say precisely what each figure represents without that additional context. No further breakdown of MAT scores or detailed vomiting rates was included in the submitted results data. It is worth noting that because this trial had only one participant group and relied on a comparison to historical data rather than a separate control group treated at the same time, the reported numbers reflect only the ondansetron group's experience. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Breast Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are scheduled to receive your own previously collected stem cells back (called an autologous stem cell transplant).
- You speak and understand English.
- Your stem cell infusion is planned to take place at the SCCA outpatient clinic.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have had a previous stem cell transplant using your own cells in the past.
- You do not speak English.
- Your stem cell infusion is planned to take place at the UWMC inpatient unit rather than the outpatient clinic.
- Your stem cells are planned to be thawed and specially washed to remove a preservative chemical called DMSO before being given to you.
- You have had an allergic reaction or a bad reaction to a medication called ondansetron (a common anti-nausea drug) in the past.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.